This site is intended for health professionals only
Friday 26 April 2019
Share |

Topic: Psychiatry

August 26, 2015
First long-acting treatment to be administered four times a year for the treatment of schizophrenia in adults

Janssen-Cilag International NV (Janssen) announced the submission of an extension marketing authorisation application (MAA) to the European Medicines Agency (EMA) for paliperidone palmitate once-every-three-months formulation for the treatment of schizophrenia. If approved, it will be the first antipsychotic schizophrenia medication to be administered four times a year.

 

August 10, 2015
Antipsychotics remain the mainstay of long-term treatment for schizophrenia. This article gives a brief overview of the commonly used antipsychotics, summarises the evidence and describes the key differences between them

 

July 24, 2015
Importantly, each patient is treated as an individual and decisions about their medication are always patient-centred.

I have recently started a new post with Wye Valley NHS Trust in Herefordshire.

 

Herefordshire is a beautiful rural county in the west of England nestling in the shadow of the Black Mountains on the Welsh border.

 

I am contracted to provide a service to the Mental Health Trust whilst being based in the Acute Hospital Pharmacy. Although this is a new post for Herefordshire, I have been doing mental health pharmacy since the late 1990s.

 

March 31, 2015
Takeda Pharmaceuticals International GmbH and Sunovion Pharmaceuticals Inc. announced the results from three post-hoc analyses evaluating the efficacy and safety of Latuda® (lurasidone) in patients with schizophrenia at the 23rd European Congress of Psychiatry (EPA). The analyses suggest that lurasidone is associated with reduced hostility in patients with schizophrenia and reduced frequency of certain adverse events commonly associated with antipsychotic treatment.

Takeda Pharmaceuticals International GmbH and Sunovion Pharmaceuticals Inc. announced the results from three post-hoc analyses evaluating the efficacy and safety of Latuda® (lurasidone) in patients with schizophrenia at the 23rd European Congress of Psychiatry (EPA). The analyses suggest that lurasidone is associated with reduced hostility in patients with schizophrenia and reduced frequency of certain adverse events commonly associated with antipsychotic treatment.

June 12, 2014
Janssen-Cilag International NV announced that the EC has approved an extension of the oral atypical antipsychotic INVEGA (paliperidone ER) schizophrenia indication, to include adolescents aged 15 years and older.

Janssen-Cilag International NV announced that the EC has approved an extension of the oral atypical antipsychotic INVEGA® (paliperidone ER) schizophrenia indication, to include adolescents aged 15 years and older.

The decision from the EC follows a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency in April 2014.

December 12, 2013
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co Ltd. (Otsuka) has announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate against Alzheimer’s disease.

 

November 21, 2013
H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co, Ltd. (Otsuka) have announced marketing authorisation approval from the European Commission for Abilify Maintena (aripiprazole), an intramuscular (IM) once-monthly injectable formulation for maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole.

 

October 1, 2013
H. Lundbeck A/S (Lundbeck) and Takeda Pharmaceutical Company Limited (Takeda) have jointly announced that the US Food and Drug Administration (FDA) has approved Brintellix™ (vortioxetine) for the treatment of adults with major depressive disorder (MDD), a debilitating mental health illness affecting approximately 14 million adult Americans in a given year.

 

May 20, 2013
H Lundbeck A/S (Lundbeck) and partner Takeda Pharmaceutical Company Limited (Takeda) have announced that the companies will be presenting new data on four pivotal studies on vortioxetine, a novel investigational drug under review by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of major depression. The phase III data will be presented at the 2013 Annual Meeting of the American Psychiatric Association (APA) in San Francisco, USA.

teaser

April 10, 2013
H. Lundbeck A/S (Lundbeck) has announced positive results for the REVIVE study, a double-blind randomised study of Brintellix

teaser

April 10, 2013
H. Lundbeck A/S (Lundbeck) has announced the results of the revised analysis of the Phase III programme that formed the basis for the approval of Selincro

teaser

April 2, 2013
Pharmacists could become key players in recommending pharmacogenetic testing and interpreting test results, and it is essential that pharmacy schools start training programmes in the management, application and delivery of this information

teaser

March 7, 2013
Otsuka Pharmaceutical Co Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) have outlined co-promotion plans and summarised the overall progress in their global alliance at a session in Japan with representatives from domestic and international media organisations.

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine